drugset / Trial / NCT00836654

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

NCT00836654 ↗

Phase 2/3 Completed 258 enrolled Neovii Biotech
RandomizedCrossoverOpen-labelTreatment

Summary

The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.

Timeline

Start
2004-09
Primary completion
2006-11
Completion
2006-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Catumaxomab Monoclonal antibody — —

Indications